摘要:
The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5′ triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
摘要:
The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5′ triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
摘要:
The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5′ triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
摘要:
Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
摘要:
An apparatus (1) and a method serve for precision rolling of a surface area (2) of a rotationally symmetrical component (3), especially a screw. The apparatus (1) includes at least two spaced apart rolling tools (4, 5), a measuring unit (9) for determining an actual blank diameter of the component (3), an evaluating unit (10) for comparing the determined actual blank diameter of the component (3) with a predetermined blank diameter and for determining an adjustment value from the result of the comparison, and a control unit (11) for adjusting a distance between the at least two rolling tools (4, 5) in response to the adjustment value.
摘要:
A method for operation of an ion beam therapy system that comprises a grid scanner device, arranged in a beam guidance system (6, 8), having vertical deflection means (13) and horizontal deflection means (14) for the vertical and horizontal deflection of a treatment beam (11) perpendicular to its beam direction, with the result that the treatment beam (11) is deflected by the grid scanner device to an isocentre (10) of the irradiation site and scans a specific area surrounding the isocentre (10) using a specific radiation dose. Both the depth dose distribution and the transverse dose distribution of the grid scanner device (13, 14) at various positions in the region of the isocentre (10) are measured and evaluated, it being concluded that the radiation dose distribution is adequately homogeneous if the degree of variation in the radiation dose values measured at the individual positions does not exceed a specific tolerance limit value.
摘要:
The present invention relates to a method of checking an isocentre and a patient-positioning device of an ion beam therapy system that comprises a grid scanner device, arranged in a beam guidance system, having vertical deflection means and horizontal deflection means for the vertical and horizontal deflection of a treatment beam perpendicular to its beam direction, with the result that the treatment beam is deflected by the grid scanner device onto an isocentre of the irradiation site, and a specific area surrounding the isocentre is scanned, wherein a check of the isocentre and a patient-positioning device is carried out and the patient-positioning device comprises a patient table rotatable about an axis of rotation of the table. For the checking, a target point within a spherical phantom is represented by means of a special specimen body and the centre point of the specimen body is visibly represented by means of several image-forming methods. On departure of the measurement results in respect of the spatial position of the centre point under the image-forming methods from a predetermined intervention threshold, the ion beam therapy system is subjected to an inspection and/or maintenance.
摘要:
Tis invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.
摘要:
The invention describes a method of determining whether a double stranded RNA (dsRNA) silences gene expression in a cell in vivo by an RNA interference (RNAi) mechanism by performing 5′-rapid amplification of cDNA ends (5′RACE) to detect the cleavage site of the mRNA in the RNA sample.
摘要:
The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.